FDA Grants Cartesian Special Protocol for Phase 3 Trial in Myasthenia Gravis
Cartesian Therapeutics (NASDAQ: RNAC) received FDA approval under the Special Protocol Assessment (SPA) process for the Phase 3 AURORA...
Adaptive Clinical Trial Design Adaptive Trial Design Addiction Psychiatry AI in Clinical Trials alcohol use disorder Alzheimer's Disease Article Clinical Operations Clinical Research Clinical Trial Design Clinical Trial Operations Clinical Trial Ops Brief Clinical Trial Quality Clinical Trials CLINOPS WATCHDOG CNS Drug Development CNS Trials Conference Coverage Decentralized Clinical Trials Digital Health Technologies dual diagnosis eClinical Tech News eClinical Technology EMA Executive Interviews FDA Enforcement FDA Guidance FDA Real-World Evidence FDA Regulation FDA Regulatory Strategy GCP Compliance GLP-1 Receptor Agonists Ketamine Therapy Oncology Trials Opinion Parkinson's Disease Platform Trials Psilocybin MDMA Psychedelic Clinical Trials PSYCH PULSE Real-World Evidence site activation Site Operations study startup Treatment-Resistant Depression
Cartesian Therapeutics (NASDAQ: RNAC) received FDA approval under the Special Protocol Assessment (SPA) process for the Phase 3 AURORA...
Adagene Inc. announced positive updated clinical data for ADG126 (muzastotug), an anti-CTLA-4 SAFEbody® drug, combined with pembrolizumab in a...
Ocugen has received FDA approval to begin a Phase 1 clinical trial for OCU500, an inhaled and nasal spray...
Novotech, a full-service international contract research organization (CRO), released a white paper analyzing global clinical trial trends in oncolytic...
Allurion Technologies, a company focused on obesity treatment, announced a registered direct offering of 1,240,000 shares of common stock...
Merck and Eisai announced results from the Phase 3 LEAP-015 trial, which examined the efficacy of Keytruda plus Lenvima...
Exelixis announced positive results from a subgroup analysis of the phase 3 CABINET study, showing cabozantinib improved progression-free survival...
Median Technologies secured a non-binding term sheet with the European Investment Bank (EIB) for a loan of up to...
Elevar Therapeutics announced positive results from a post-hoc analysis of the CARES-310 study, showing that camrelizumab plus rivoceranib provides...
Axiom Brain Health, in partnership with the Global Alzheimer’s Platform Foundation (GAP), launched its newly renovated research facility in...